| Thyroid carcinoma
Retevmo vs Gavreto
Side-by-side clinical, coverage, and cost comparison for thyroid carcinoma.Deep comparison between: Retevmo vs Gavreto with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsGavreto has a higher rate of injection site reactions vs Retevmo based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Gavreto but not Retevmo, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Retevmo
Gavreto
At A Glance
Oral
Twice daily
RET kinase inhibitor
Oral
Once daily
RET kinase inhibitor
Indications
- Non-Small Cell Lung Carcinoma
- Medullary carcinoma of thyroid
- Thyroid carcinoma
- Metastatic Lung Non-Small Cell Carcinoma
- Thyroid carcinoma
Dosing
Non-Small Cell Lung Carcinoma, Medullary carcinoma of thyroid, Thyroid carcinoma Adults and adolescents >= 12 years: 120 mg orally twice daily (< 50 kg) or 160 mg orally twice daily (>= 50 kg); pediatric patients 2 to < 12 years: 40 mg three times daily to 160 mg twice daily orally based on body surface area; administered until disease progression or unacceptable toxicity.
Metastatic Lung Non-Small Cell Carcinoma, Thyroid carcinoma 400 mg orally once daily on an empty stomach (no food intake for at least 2 hours before and at least 1 hour after); continue until disease progression or unacceptable toxicity.
Contraindications
—
—
Adverse Reactions
Most common (>=25%) edema, diarrhea, fatigue, dry mouth, hypertension, abdominal pain, constipation, rash, nausea, headache
Serious hepatotoxicity, interstitial lung disease/pneumonitis, hypertension, QT interval prolongation, hemorrhagic events, hypersensitivity, tumor lysis syndrome, impaired wound healing, hypothyroidism, slipped capital femoral epiphysis in adolescents
Postmarketing Stevens-Johnson Syndrome
Most common (>=25%) Musculoskeletal pain, constipation, hypertension, diarrhea, fatigue, edema, pyrexia, cough
Serious ILD/Pneumonitis, hypertension, hepatotoxicity, hemorrhagic events, tumor lysis syndrome, impaired wound healing, embryo-fetal toxicity
Pharmacology
Selpercatinib is a kinase inhibitor that selectively inhibits wild-type RET and multiple mutated RET isoforms (including gene fusions and activating point mutations) as well as VEGFR1 and VEGFR3, and at clinically achievable concentrations also inhibits FGFR1, 2, and 3, blocking constitutive RET signaling that acts as an oncogenic driver promoting tumor cell proliferation.
Pralsetinib is a kinase inhibitor of wild-type RET and oncogenic RET fusions and mutations (IC50s <0.5 nM), blocking downstream signaling pathways that drive uncontrolled tumor cell proliferation in RET fusion-positive NSCLC and thyroid cancer.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
No coverage data available for Retevmo.
Gavreto
- Covered on 5 commercial plans
- PA (12/12) · Step Therapy (0/12) · Qty limit (11/12)
UnitedHealthcare
Retevmo
- Covered on 4 commercial plans
- PA (6/8) · Step Therapy (0/8) · Qty limit (6/8)
Gavreto
- Covered on 4 commercial plans
- PA (6/8) · Step Therapy (0/8) · Qty limit (6/8)
Humana
Retevmo
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (0/3) · Qty limit (2/3)
Gavreto
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (0/3) · Qty limit (2/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
No savings programs available for Retevmo.
Cost estimate not availableAssistance Fund: Non-Small Cell Lung Cancer (NSCLC)
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
RetevmoView full Retevmo profile
GavretoView full Gavreto profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.